CME: Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC

Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC

Take Post-Test

If you’ve already completed the activity.

Overview
Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-generation sequencing (NGS) has expanded the understanding of actionable molecular alterations, and in tandem has accelerated the development of drugs to inhibit alterations with greater specificity, leading to the development of novel target-selected agents in NSCLC.
The NCCN Guidelines strongly advise assessment of at least 8 targets for NSCLC by NGS, including MET exon 14–skipping mutations (METex14). The FDA has approved two MET inhibitors, capmatinib and tepotinib, for patients with METex14 metastatic NSCLC, and there is ongoing research for other targeted agents. Studies have established that treatment with MET-targeted therapies improves outcomes in patients with METex14, as opposed to patients receiving chemotherapy and/or immunotherapy, which generate a modest activity response.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. That’s why this activity will provide expert answers to questions asked by clinicians during a recent educational series on advances with selective MET Inhibitors in METex14-altered NSCLC.
Disclosure of Relevant Financial Relationships
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form of Speaker: Genentech, Inc; AstraZeneca Pharmaceuticals LP; Jazz Pharmaceuticals plc; Janssen Oncology; Bristol-Myers Squibb Co; GI Therapeutics; Takeda Oncology; and Guardant Health, Inc. Contracted research: Genentech, Inc; Spectrum Pharmaceuticals, Inc; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corp; Daiichi-Sankyo, Inc; and BeiGene LTD.
Patrick Forde, MBBCh, reported a financial interest/relationship or affiliation in the form of Advisory board: Amgen, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Co; Daiichi-Sankyo, Inc; F-Star; G1 Therapeutics; Genentech, Inc; Iteos; Janssen Oncology; Merck & Co, Inc; Novartis Pharmaceuticals Corp; Sanofi; and Surface. Research grant: AstraZeneca Pharmaceuticals LP; BioNTech; Bristol-Myers Squibb Co; Corvus; Kyowa; Novartis Pharmaceuticals Corp; and Regeneron Pharmaceuticals, Inc. Data and safety monitoring board: Polaris. Trial Steering Committee: AstraZeneca Pharmaceuticals LP, and Bristol-Myers Squibb Co.
Karen L. Reckamp, MD, MS, reported a financial interest/relationship or affiliation in the form of Consultant: Amgen, Inc; AstraZeneca Pharmaceuticals LP; Blueprint Medicines; Daiichi-Sankyo, Inc; EMD Serono, Inc; Genentech, Inc; GlaxoSmithKline; Janssen Oncology; Lilly USA; Merck KGA; Mirati Therapeutics; Seattle Genetics, Inc; Takeda Oncology; and Tesaro, Inc. Research funding to institution: Genentech, Inc; Blueprint Medicines; Calithera Biosciences Inc; Daiichi-Sankyo, Inc; Elevation Oncology; and Janssen Oncology.
The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C ; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.
Target Audience
This educational activity designed for medical oncologists, thoracic oncologists, pathologists, pulmonologists, advanced practitioners (nurses, pharmacists, physician assistants), laboratory professionals, and other healthcare professionals involved in the treatment of patients with NSCLC.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
1. Implement molecular testing for METex14–skipping events in clinical practice for all patients diagnosed with NSCLC, according to evidence-based guidelines recommendations, to identify those who would benefit from targeted therapy
2. Assess the latest clinical evidence, efficacy data, and guideline recommendations for MET targeted therapies for the treatment of METex14-skipping NSCLC
3. Devise mitigation strategies for the identification and management of treatment-related adverse events associated with METex14-directed therapies
Accreditation and Credit Designation Statements
ACCREDITED CONTINUING EDUCATION
Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 12/27/23. PAs should only claim credit commensurate with the extent of their participation.

Credit Designation for Pharmacists
This knowledge-based activity is approved for 0.25 contact hour of continuing pharmacy education JA4008106-0000-22-049-H01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Laboratory Professionals
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.25 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Provider(s)/Educational Partner(s)
Provided by AXIS Medical Education.
Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Method of Participation and Request for Credit
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
CME/CE
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
0.50 credits
- Guy Young, MD
  Peer
0.50 credits
Incorporating Scientific Advances into Myelofibrosis Treatment Plans
Incorporating Scientific Advances into Myelofibrosis Treatment Plans
CME/CE
Incorporating Scientific Advances into Myelofibrosis Treatment Plans
1.00 credit
- Ruben Mesa, MD, FACP
  Peer
1.00 credit
Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS
Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS
CME/CE
Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS
0.25 credits
- Paul P. Doghramji, MD, FAAFP
  Peer
- Rami Komrokji, MD
  Peer
- Allan Platt, PA-C, MMSc
  Peer
0.25 credits
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
CME/CE Broadcast Replay
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
1.00 credit
- Neeraj Agarwal, MD
  Peer
1.00 credit